Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: KLH who wrote (2444)	1/12/1999 11:28:00 PM
From: Machaon	Respond to of 2553

<< I'm holding my breath >> So am I. I'm also hoping that we get some positive results from their pipeline. To me, GENZL is really undervalued when you consider that it is an intrinsic part of GENZ and not a separate company. Thus GENZ should be able to fund GENZL's pipeline thru profitability. A lot of small, unsupported biotechs are going to encounter major fund crunches in 1999.

To: KLH who wrote (2444)	1/13/1999 9:18:00 AM
From: Machaon	Read Replies (1) \| Respond to of 2553

Well, stop holding your breath! Early release of positive data from GENZL! About 25% sequential growth in Carticel worldwide, and about 22% growth in the US. 81% annual growth in Carticel and a 56% annual growth in Revenues. Very good report! This is the first report that shows, not only, significant growth both also that their predictions, from the last conference call, were right on the mark! In fact, their predictions were a little low. That's probably why they issued an early release of good numbers. It's about time! biz.yahoo.com